East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
Japan-Based International Drug Developer Awards $2 Million
Thorough QT Study to eResearchTechnology
Agreement Marks Another Significant Contract With a Japanese Drug Developer
Demonstrating Continued Momentum of ICH, E14 Global Adoption
PHILADELPHIA, June 27 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has been
awarded a Thorough QT (T-QT) Study valued at more than $2 million in cardiac
safety monitoring and services from the U.S. subsidiary of a leading
Japan-based drug developer for one of its compounds in clinical trials.
The contract follows an agreement with another Japan-based sponsor for a $1.6
million T-QT Study eRT announced last week, signaling momentum for global
adoption of the recently finalized International Conference on Harmonisation
(ICH), E14 cardiac safety guidance.
eRT is providing comprehensive support, including provision of digital 12-lead
ECG equipment designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.
"eRT is uniquely qualified to provide this sponsor with a turnkey solution to
ensure compliance with the recently ratified ICH, E14 guidance for cardiac
safety in new drug development," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT. "In addition to Best
Practice cardiac safety services, eRT also facilitated expert scientific
consulting on study design, leveraged its Certified Clinical Pharmacology Unit
Partner Program, and included a partner specializing in bio-statistics services
focused on T-QT Study requirements. eRT's ability to assemble a best of breed
team comprised of individuals and organizations who have worked together
closely across many T-QT studies delivered a compelling value proposition for
this customer."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial outlooks stated
herein. Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473;
or Matt Hayden of Hayden Communications, +1-858-704-5065, for
eResearchTechnology, Inc.
Web site: http://www.ert.com/